Claims extracted
19
sentences that state something as happening or true
Uncertain
16%
3 of 19 hedged
("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
New York Post's corrections and
hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
A breakthrough treatment has made significant progress, showing promising results in decreasing recurrence and death from a devastating disease.
asserted
treatment → make → disease
Led by researchers from NYU Langone Health and its Perlmutter Cancer Center, the landmark international study looked at the effects of anti-cancer medicine sacituzumab tirumotecan (sac-TMT) compared to standard chemotherapy drugs.
asserted
study → lead → drugs
The results of the phase 3 trial could offer hope for a disease that kills more than 97,000 people around the world each year.
uncertain
that → offer → world
The most common cancer in the female reproductive system, endometrial cancers are becoming deadlier, yet have few effective treatment options, especially if diagnosed at a later stage.
asserted
cancers → become → stage
The study compared sac-TMT to standard chemotherapy drugs for advanced or recurrent endometrial cancer in women who had already been treated with an established PD-1 inhibitor drug that makes cancer cells more visible to immune system attack.
asserted
cells → compare → attack
The ones treated with the investigational drug had a 41% lower risk of their cancer progressing and spreading to other parts of the body than chemo alone, and a 32% lower overall risk of death.
asserted
cancer → treat → death
Meanwhile, 35% of women treated with sac-TMT showed positive responses, including tumor shrinkage, more than twice that of those who underwent standard chemotherapy.
“These positive results from the first phase 3 trial using sacituzumab tirumotecan after immunotherapy establishes this drug as a new standard treatment in recurrent endometrial cancer,” study principal investigator Bhavana Pothuri said in a press release.
asserted
Pothuri → treat → release
Sac-TMT is designed to attach to the trophoblast cell-surface antigen 2 (Trop-2) protein that sits on the surface of endometrial cancer cells.
asserted
that → design → cells
As an antibody-drug conjugate, the new drug is a targeted cancer therapy that delivers more drug to tumor cells while limiting damage to healthy cells.
asserted
that → target → cells
The treatment wasn’t without side effects, though, with the most frequent ones including low blood counts, inflammation in the mouth and dry or itchy eyes.
asserted
ones → include → mouth
Still, the researchers reported all of the adverse effects were manageable.
asserted
all → report → effects
The positive results of the study also show promise for use of the sac-TMT drug in other cancers with excessive amounts of Trop-2, such as lung, breast, ovarian and intestinal tumors.
asserted
results → show → tumors
The study from NYU Langone showed similar results to another phase 3 clinical trial conducted by drugmaker Merck back in May.
uncertain
study → show → May
The TroFuse-005 trial was the first global trial to “demonstrate statistically significant improvement” from sacituzumab tirumotecan compared to chemotherapy, according to a Merck press release.
uncertain
trial → demonstrate → release
More than 770 patients with endometrial cancer received either sac-TMT every two weeks or a treatment of the physician’s choice, including doxorubicin or paclitaxel chemotherapy.
asserted
patients → receive → doxorubicin
Those who were administered sac-TMT showed “clinically meaningful improvement” in their disease state compared to the treatment of the physician’s choice.
asserted
who → administer → choice
While Merck didn’t disclose any statistics on exact survival benefit, response rate, side effect rates or other details, they reported the drug met response rate benchmarks and exhibited similar side effects to earlier studies.
asserted
drug → disclose → studies
As a result of the Merck clinical trial and the NYU Langone study, Pothuri recommends that “clinical guidelines for endometrial cancer will need to be reassessed to incorporate sacituzumab tirumotecan.
asserted
guidelines → recommend → tirumotecan
“Our study offers much-needed hope to women worldwide living with endometrial cancer, which is increasing in both incidence and mortality,” study co-investigator Michelle Lightfoot, an assistant professor at NYU Grossman School of Medicine, said in a press release.
asserted
Lightfoot → offer → release
The Aporia
